Intellectual Property India Publishes Patent Application for Methods, Reagents And Kits For Detecting Minimal/Measurable Disease In T-Cell Acute Lymphoblastic Leukemia (t-All) And T-Cell Lymphoblastic Lymphoma (t-Lbl)

MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202617052555 A) filed by Stichting Euroflow on April 24, 2026, for Methods, Reagents And Kits For Detecting Minimal/Measurable Disease In T-Cell Acute Lymphoblastic Leukemia (t-All) And T-Cell Lymphoblastic Lymphoma (t-Lbl).

Inventors include Orfao De Matos Correia E Vale, Jos Alberto; Szczepanski, Tomasz; Sedek, Lukasz; Soriano Rodriguez, Beatriz; Lhermitte, Ludovic Bernard Simon; Brggemann, Monika Ursula Helga; Kohlscheen, Saskia; Kalina, Tom; Reiterov, Michaela; Nierkens, Stefan; Gaipa, Giuseppe; De Sa Ferreira Facio, Cristiane; Almeida Parra, Julia Maria; and Van Dongen, Jacobus Johannes Maria.

The application for the patent was published on August 07, 2026, under issue no. 32/2026.

Abstract: The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.

Disclaimer: Curated by HT Syndication.